Galectin Therapeutics Inc (GALT)

3.16
0.07 2.30
NASDAQ : Health Care
Prev Close 3.09
Open 3.15
Day Low/High 3.11 / 3.23
52 Wk Low/High 1.08 / 3.33
Volume 271.77K
Avg Volume 713.80K
Exchange NASDAQ
Shares Outstanding 34.06M
Market Cap 110.03M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting GALT Put Options For May 19th

Interesting GALT Put Options For May 19th

Investors in Galectin Therapeutics Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALT options chain for the new May 19th contracts and identified the following put contract of particular interest.

Combination Immunotherapy With Galectin-3 Inhibitor GR-MD-02 Enhances Effects In Pre-clinical Models And Early Results Of Phase 1 Clinical Trials

Combination Immunotherapy With Galectin-3 Inhibitor GR-MD-02 Enhances Effects In Pre-clinical Models And Early Results Of Phase 1 Clinical Trials

First-in-human data presented at GTCBio 9th Immunotherapeutics & Immunomonitoring Conference

Galectin Therapeutics Announces $4 Million In New Equity Financings

Galectin Therapeutics Announces $4 Million In New Equity Financings

Common and Preferred private placements completed at above market prices

Galectin Therapeutics Announces Positive New Psoriasis And Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships For Therapy Of Severe Skin Diseases

Galectin Therapeutics Announces Positive New Psoriasis And Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships For Therapy Of Severe Skin Diseases

Meaningful activity of GR-MD-02 in treating psoriasis and preliminary data in treating atopic dermatitis suggests promise in treatment of serious skin disease

Galectin Therapeutics To Present Clinical Data On Selective Non-Invasive Tests For The Development Of Novel Therapies For Nonalcoholic Steatohepatitis

Galectin Therapeutics To Present Clinical Data On Selective Non-Invasive Tests For The Development Of Novel Therapies For Nonalcoholic Steatohepatitis

Research to be presented at The Liver Meeting® 2016 demonstrates correlation of FibroScan and MRE as non-invasive tests to assess the progression of liver fibrosis and cirrhosis

Galectin Therapeutics (GALT) Stock Drops on Drug Failure, Downgraded

Galectin Therapeutics (GALT) Stock Drops on Drug Failure, Downgraded

H.C. Wainwright reduced Galectin Thereapeutics' (GALT) stock rating to 'neutral' after the company's fatty liver disease drug failed in a phase II clinical trial.

Galectin Therapeutics (GALT) Stock Declines on Drug Failure, Rating Cut

Galectin Therapeutics (GALT) Stock Declines on Drug Failure, Rating Cut

Galectin Therapeutics' (GALT) stock rating was cut two notches to 'sell' at Roth Capital on Wednesday after the company's drug for fatty liver disease failed a clinical trial.

5 Stocks Under $10 That Could Make You a Lot of Money

5 Stocks Under $10 That Could Make You a Lot of Money

These stocks trading for less than $10 a share are within range of triggering big breakout trades. Here's how to trade them from here.

These Biotech Names Are on My Radar

These Biotech Names Are on My Radar

But I'm expecting that things will slow into the Fed news.

Galectin Therapeutics Announces Results From 12-Week Extension Of Phase 2a Psoriasis Clinical Trial

Galectin Therapeutics Announces Results From 12-Week Extension Of Phase 2a Psoriasis Clinical Trial

Meaningful activity of GR-MD-02 in treating psoriasis suggests promise in treatment of non-alcoholic steatohepatitis (NASH), the company's primary target